<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02563860</url>
  </required_header>
  <id_info>
    <org_study_id>2014-4253</org_study_id>
    <nct_id>NCT02563860</nct_id>
  </id_info>
  <brief_title>Pharmacological Treatment of Rett Syndrome With Statins</brief_title>
  <acronym>Statins</acronym>
  <official_title>Pharmacological Treatment of Rett Syndrome With 3-Hydroxy-3 Methylglutaryl-coenzyme A Reductase Inhibitor-Lovastatin (Mevacor)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rett Syndrome Research Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2 , open label, dose escalating study of Lovastatin in Rett syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Excess neuronal cholesterol plays a role in the pathophysiology of Rett syndrome(RTT) and the
      investigators hypothesise that inhibition of cholesterol synthesis in the CNS will reduce
      neuronal cholesterol and lead to improvement in Rett syndrome related symptoms.

      Goal: To determine the optimal dosing regiment of Lovastatin for patients with RTT and to
      identify the most appropriate primary outcome measure for the subsequent Phase 3 study.

      Phase 2, dose escalation study.

      Primary outcome: Gait speed Secondary outcomes: respiratory function, cognition, EEG
      (encephalopathy), Rett syndrome severity scale, neurodevelopmental assessment (QOL)

      20 ambulatory female patients with genetically confirmed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gait Velocity as Measured by GAITRite System</measure>
    <time_frame>During final week of treatment, week 32</time_frame>
    <description>To perform quantitative gait assessment using a computerized walkway with embedded pressure sendors (GAIT rite)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Memory Novelty Score as Assessed by TobiiTX 300 Eyetracking System</measure>
    <time_frame>final week of treatment, Week 32</time_frame>
    <description>Novelty score is considered a composite measure of visual memory.Test is a standardized neuropsychological test( &quot;Rose test&quot;) adapted for eye tracking system.
The present study made use of a well-established battery of &quot;visual paired comparison&quot; problems .There were nine problems: five using achromatic photos of faces and four using multicolored abstract patterns paired stimuli , separated by 23Â°. For each problem, two identical stimuli are briefly presented side by side for familiarization, then the familiar and a new one are paired on test
Recognition(memory) is indexed by a novelty score (percentage of looking to the novel target on test).
Higher novelty scores were related to better recognition (index of better memory) Scores range from 0.0-1.0 (0-100%) and indicate 1) more overall looking at novel target and (2) more fixations to novel targets.
Score of .5 (50%) indicates looking &quot;by change&quot; only with no recognition.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Rett Syndrome</condition>
  <arm_group>
    <arm_group_label>Open label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Lovastatin, dose escalating trial according to the following schedule:
10 mg daily for 8 week 20 mg daily for 8 weeks 40 mg daily for 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lovastatin</intervention_name>
    <description>dose escallating</description>
    <arm_group_label>Open label</arm_group_label>
    <other_name>Mevacor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females patients,

          -  Genetically confirmed RTT,

          -  Ambulatory.

        Exclusion Criteria:

          -  Presence of co morbid non-Rett related disease,

          -  History of adverse reaction/hypersensitivity to statins,

          -  Levels of aspartate-amino trans-ferase (AST), alanine-amino transferase (ALT) or
             creatine kinase (CK) triple the normal values,

          -  Active liver disease,

          -  Concomitant use of strong CYP3A4 inhibitors,

          -  Condition predis-posing to renal failure secondary to rhabdomyolysis (scoliosis
             surgery within 6 months),

          -  Oral contraceptives use.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aleksandra Djukic, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 20, 2015</study_first_submitted>
  <study_first_submitted_qc>September 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2015</study_first_posted>
  <results_first_submitted>May 19, 2018</results_first_submitted>
  <results_first_submitted_qc>April 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 7, 2019</results_first_posted>
  <last_update_submitted>July 11, 2019</last_update_submitted>
  <last_update_submitted_qc>July 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Aleksandra Djukic</investigator_full_name>
    <investigator_title>Professor of Clinical Neurology, Director, Tri State Rett Syndrome Center</investigator_title>
  </responsible_party>
  <keyword>Treatment trial</keyword>
  <keyword>Lovastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rett Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lovastatin</mesh_term>
    <mesh_term>L 647318</mesh_term>
    <mesh_term>Dihydromevinolin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Open Label</title>
          <description>Treatment with Lovastatin, dose escalating trial according to the following schedule:
All participants were assigned to the specified sequence of interventions and all participants received all the three dosing regimen please make this explicit in the Arm/Group Description. In either case, separate Period 1-10 mg daily for 8 week Period 2-20 mg daily for 8 weeks Period 3-40 mg daily for 16 weeks.
Lovastatin: dose escallating</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Open Label</title>
          <description>Female patients with genetically confirmed RTT, treatment arm only.
Treatment with Lovastatin, dose escalating trial according to the following schedule:
10 mg daily for 8 week 20 mg daily for 8 weeks 40 mg daily for 16 weeks.
Lovastatin: dose escallating</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Gait Velocity as Measured by GAITRite System</title>
        <description>To perform quantitative gait assessment using a computerized walkway with embedded pressure sendors (GAIT rite)</description>
        <time_frame>During final week of treatment, week 32</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Open Label</title>
            <description>Treatment with Lovastatin, dose escalating trial according to the following schedule:
10 mg daily for 8 week 20 mg daily for 8 weeks 40 mg daily for 16 weeks.
Lovastatin: dose escallating</description>
          </group>
        </group_list>
        <measure>
          <title>Gait Velocity as Measured by GAITRite System</title>
          <description>To perform quantitative gait assessment using a computerized walkway with embedded pressure sendors (GAIT rite)</description>
          <units>cm/sec</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6" lower_limit="43.8" upper_limit="71.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Memory Novelty Score as Assessed by TobiiTX 300 Eyetracking System</title>
        <description>Novelty score is considered a composite measure of visual memory.Test is a standardized neuropsychological test( &quot;Rose test&quot;) adapted for eye tracking system.
The present study made use of a well-established battery of &quot;visual paired comparison&quot; problems .There were nine problems: five using achromatic photos of faces and four using multicolored abstract patterns paired stimuli , separated by 23Â°. For each problem, two identical stimuli are briefly presented side by side for familiarization, then the familiar and a new one are paired on test
Recognition(memory) is indexed by a novelty score (percentage of looking to the novel target on test).
Higher novelty scores were related to better recognition (index of better memory) Scores range from 0.0-1.0 (0-100%) and indicate 1) more overall looking at novel target and (2) more fixations to novel targets.
Score of .5 (50%) indicates looking &quot;by change&quot; only with no recognition.</description>
        <time_frame>final week of treatment, Week 32</time_frame>
        <population>Calculation done on intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label</title>
            <description>Treatment with Lovastatin, dose escalating trial according to the following schedule:
10 mg daily for 8 week 20 mg daily for 8 weeks 40 mg daily for 16 weeks.
Lovastatin: dose escallating</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Memory Novelty Score as Assessed by TobiiTX 300 Eyetracking System</title>
          <description>Novelty score is considered a composite measure of visual memory.Test is a standardized neuropsychological test( &quot;Rose test&quot;) adapted for eye tracking system.
The present study made use of a well-established battery of &quot;visual paired comparison&quot; problems .There were nine problems: five using achromatic photos of faces and four using multicolored abstract patterns paired stimuli , separated by 23Â°. For each problem, two identical stimuli are briefly presented side by side for familiarization, then the familiar and a new one are paired on test
Recognition(memory) is indexed by a novelty score (percentage of looking to the novel target on test).
Higher novelty scores were related to better recognition (index of better memory) Scores range from 0.0-1.0 (0-100%) and indicate 1) more overall looking at novel target and (2) more fixations to novel targets.
Score of .5 (50%) indicates looking &quot;by change&quot; only with no recognition.</description>
          <population>Calculation done on intent-to-treat population</population>
          <units>percent</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.85" lower_limit="25.85" upper_limit="68.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.93" lower_limit="47.55" upper_limit="70.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Open Label</title>
          <description>Treatment with Lovastatin, dose escalating trial according to the following schedule:
10 mg daily for 8 week 20 mg daily for 8 weeks 40 mg daily for 16 weeks.
Lovastatin: dose escallating</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>mild</sub_title>
                <description>Anxiety, upon dose escalation from 20 to 40 mg of Lovastatin.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Aleksandra Djukic</name_or_title>
      <organization>Montefiore MC</organization>
      <phone>7189204378</phone>
      <email>adjukic@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

